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Abstract
Amorphous Calcium Phosphate (ACP) is an essential mineral phase formed in mineralized tissues and the first
commercial product as artificial hydroxyapatite. ACP is unique among all forms of calcium phosphates in that it
lacks long-range, periodic atomic scale order of crystalline calcium phosphates. The X-ray diffraction pattern is
broad and diffuse with a maximum at 25 degree 2 theta, and no other different features compared with well-
crystallized hydroxyapatite. Under electron microscopy, its morphological form is shown as small spheroidal
particles in the scale of tenths nanometer. In aqueous media, ACP is easily transformed into crystalline phases such
as octacalcium phosphate and apatite due to the growing of microcrystalline. It has been demonstrated that ACP
has better osteoconductivity and biodegradability than tricalcium phosphate and hydroxyapatite in vivo. Moreover,
it can increase alkaline phosphatase activities of mesoblasts, enhance cell proliferation and promote cell adhesion.
The unique role of ACP during the formation of mineralized tissues makes it a promising candidate material for
tissue repair and regeneration. ACP may also be a potential remineralizing agent in dental applications. Recently
developed ACP-filled bioactive composites are believed to be effective anti-demineralizing/remineralizing agents
for the preservation and repair of tooth structures. This review provides an overview of the development, structure,
chemical composition, morphological characterization, phase transformation and biomedical application of ACP in
dentistry.
1. Review
Amorphous calcium phosphate (ACP) is the initial solid
phase that precipitates from a highly supersaturated cal-
cium phosphate solution, and can convert readily to
stable crystalline phases such as octacalcium phosphate
or apatitic products. Its morphological form, structural
model and X-ray diffraction patterns are typical for non-
crystalline substances with short-range periodic regular-
ity. ACP has been demonstrated to have better in vivo
osteoconductivity than hydroxyapatite (HAP), better bio-
degradability than tricalcium phosphate, good bioactivity
but no cytotoxicity [1]. These excellent biological prop-
erties make ACP widely used in dentistry, orthopaedics
and medicine. This review provides an overview of the
development, structure, composition and morphology
characterization, phase transformation and biomedical
application of ACP in dentistry.
2. Development
Generally, it is believed that ACP was firstly described
by Aaron S. Posner [1] in the mid 1960s. It was
obtained as an amorphous precipitate by accident when
mixing high concentrations (30 mM) of calcium chlor-
ide and sodium acid phosphate (20 mM) in buffer [2].
In X-ray diffraction, it was shown to have only two
broad and diffuse peaks, with maximum at 25° 2θ.N o
other features were obvious and it was clearly not apa-
tite. This pattern is typical for substances that lack long
range periodic regularity. It was found that immediately
after being mixed, the spontaneously formed precipitate
was a non-crystalline, or amorphous, calcium phosphate
with calcium to phosphorus molar ratio (Ca/P) of 1.50.
After several hours, it could convert to poorly crystalline
apatite on ageing. Afterwards, this solid converts slowly
to crystalline apatite (Ca/P = 1.67) by an autocatalytic
mechanism [3].
In 1965, Eanes et al. identified ACP as a bone compo-
nent [2]. ACP in bone, along with the apatite, might
account for the broad diffraction pattern and variable
composition of bone minerals. An age-dependent
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with the proportion of ACP decreasing with age [3,4]. In
1975, ACP was found in the mineralized cytoplasmic
structure isolated from the blue crab hepatopancreas,
with a very similar short-range atomic structure to syn-
thetic amorphous calcium phosphate [5].
3. Structure
After the discovery of amorphous calcium phosphate,
the early studies were focused on the structure of ACP.
It was suggested that synthetic ACP particles, which
appear as 300- 1000 Å spheres in the electron micro-
scope, consist of a random assembly of ion clusters 9.5
Å in diameter, dimensions consistent with the chemical
composition of Ca9(PO4)6 [5]. And the 15-20% of water
found in synthetic amorphous calcium phosphate was
shown to be mostly in the interstices between, and not
within, the individual Ca9(PO4)6 clusters [6]. Aggregated
ACP particles readily dissolve and crystallize to form
apatite, a thermodynamically stable phase. The typical
radial distribution of noncrystalline ACP cluster struc-
tures, calculated from the x-ray diffraction patterns, is
only two broad and diffuse peaks showing the rapid
drop-off of atomic periodicity. Short-range order exists
in these amorphous structures but no long-range order
such as that in crystalline hydroxyapatite [6]. Infrared
analysis showed a similar lack of crystalline order about
the PO4 anions in the ACP structure [7].
It is now generally agreed that, both in vitro and in
vivo, precipitation reactions at sufficiently high supersa-
turation and pH result in the initial formation of an
amorphous calcium phosphate with a molar calcium/
phosphate ratio of about 1.5, with a range of 1.34-1.50
in different pH and 1.50-1.67 when adding different
amount of carbonates [8]. However, Wuthier et al
reported that ACP, with Ca/PO4 molar ratio as low as
1.15, precipitated at more acidic preparative pHs, i.e.6.9
[9].
More importantly, it has been shown that ACP parti-
cles are nanometer particles. Primary particle sizes of
ACP is about 40-100 nm. The morphology of ACP
solids appears to be a curvilinear shape when viewed by
TEM, rather than the faceted, angular shape of crystal-
line calcium phosphates. However, this curvilinear
appearance has only been clearly established with dried
ACP [10]. The initial flocculates collected immediately
after precipitation of highly hydrated ACP have a low-
contrast disk-shaped appearance. High-contrast spheri-
cal particles begin to appear as ACP suspensions age,
and become the dominant shape with time [11].
The disordered structure makes ACP highly reactive
with body fluid, resulting fast apatite reprecipitation.
Accordingly, ACP has been evidenced to have better in
vivo osteoconductivity than hydroxyapatite and better
biodegradability than tricalcium phosphate [10]. The
ACP precipitate, with little long-range order, is a highly
unstable phase and hydrolyzes almost instantaneously to
more stable phases. In the presence of other ions or
under in vivo conditions, ACP may persist for appreci-
able periods due to kinetic stabilization [12]. Although
the exact mechanism of stabilization of ACP is not
understood, the presence of Mg
2+,F
-, carbonate, pyro-
phosphate, diphosphonates, or polyphosphorylated
metabolites or nucleotides, in sufficient quantity will
prevent the transformation of synthetic ACP to hydro-
xyapatite [13,14].
4. ACP in Biomineralization
It has been stated that ACP likely plays a special role as
a precursor to bioapatite and as a transient phase in bio-
mineralization [15]. In solutions, ACP is readily con-
verted to stable crystalline phases such as octacalcium
phosphate or apatitic products. One biomineralization
strategy that has received significant attention in recent
years is mineralization via transient precursor phases
[16]. Transient amorphous mineral phases have been
detected in biomineral systems in different phyla of the
animal kingdom [17]. ACP has been previously reported
in the otoliths of blue sharks and also shown to form as
a precursor phase of carbonated hydroxyapatite in
chiton teeth [18]. The presence of an abundant ACP
phase has also been demonstrated in the newly formed
zebrafish fin bony rays [19]. The disordered phase is a
precursor of crystalline carbonated hydroxyapatite. It
was found that the initially extracted amorphous
mineral particles transformed into a crystalline mineral
phase with time, and the proportion of crystalline
mineral increased during bone maturation [19]. The
transient ACP phase may conceivably be deposited
directly inside the gap regions of collagen fibrils, but it
may also be delivered as extrafibrillar particles [19]. This
is consistent with the study that collagen mineralization
via a transient ACP precursor phase in vitro to produce
aligned intrafibrillar carbonated apatite crystals [20].
Several studies in different systems in vivo also have
reported the presence of transient precursor calcium
phosphate phases in the deposition of carbonated hydro-
xyapatite. Beniash performed a comprehensive analysis
of the mineral phases in the early secretory enamel of
the mandibular mouse incisors using four physical char-
acterization methods. It was suggested that the outer,
younger, early secretory enamel contained a transient
disordered ACP phase, which transformed with time
into the final apatitic crystalline mineral [17].
A variety of proteins and ions have been proposed to
be involved in the biomineralization of ACP to HAP
[21,22]. Dentin matrix protein1 (DMP1) is one of such
biomineralization proteins [23]. In the report of He, it
Zhao et al. Chemistry Central Journal 2011, 5:40
http://journal.chemistrycentral.com/content/5/1/40
Page 2 of 7has been shown that two peptide motifs identified in
DMP1 [motif-A (ESQES) and motif-B (QESQSEQDS)]
enhanced in vitro HAP formation when immobilized on
a glass substrate. It was demonstrated in another study
that the synthesized artificial protein composed of these
peptide motifs of DMP1 facilitated reorganization of the
internal structure of amorphous particles into ordered
crystalline states, i.e., the direct transformation of ACP
to HAP, thereby acting as a nucleus for precipitation of
crystalline calcium phosphate [24].
5. Transformation to Octacalcium Phosphate and
Apatite
Studies on the preparation of hydroxyapatite [Ca10(PO4)
6-(OH)2], the synthetic prototype of bone mineral,
showed that the precipitation of initial solid phase from
a calcium phosphate solution depends on the degree of
its supersaturation [8]. A noncrystalline ACP precursor,
approximating Ca9(PO4)6 in composition forms under
conditions of high supersaturation [1,15]. This precursor
ACP, unless stabilized in some way, transforms to ther-
modynamically more stable calcium phosphate phases
or will be taken place by an autocatalytic solution-med-
iate crystallization process. On the other hand, the first
s o l i dt of o r mi nl o ws u p e r s a t urated solutions is hydro-
xyapatite with Ca/P ratio of 1.67 obtained without pre-
cursor phases. Therefore, ACP is considered as a
“mandatory precursor to apatite”, and apatite can be
formed in dilute solutions without going through this
precursor [15]. The pH value also affects the initial solid
phase in the precipitation of calcium and phosphate
ions. Octacalcium phosphate (OCP) is the crystalline
phase that initially forms when the reaction pH is less
than 9.25, whereas apatite preferentially forms at higher
pHs [25]. It is known that ACP is often the first-formed
deposit inv i t r o , at neutral pH and moderate supersa-
turation [26]. Transformation mechanism of ACP to
apatite at physiological pH has been described as follow-
ings: firstly ACP dissolution, then a transient OCP solid
phase reprecipitation through nucleation growth, and
finally hydrolysis of the transient OCP phase into the
thermodynamically more stable apatite by a topotactic
reaction, which usually takes tens of hours [26].
Based on the analysis of the measured precipitate
induction time and the structure of the developing solid
phase, Feenstra proposed that OCP might be an inter-
mediate in the conversion of ACP to apatitic calcium
phosphate [27]. Since OCP or apatite crystals are gener-
ally found in association with ACP spherules, it is possi-
b l et h a tA C Pa c t sa sat e m p l a t ef o rt h eg r o w t ho ft h e s e
crystal phases. Their formation, however, appears to take
place by consuming ions largely supplied from the sur-
rounding solution, rather than from direct hydrolysis of
the solid amorphous material. At pH 10, transformation
of ACP to poorly crystalline HAP may proceed without
changes in the local calcium environment, but with the
development of longer range order in the structure.
However, in contrast to these results at pH = 10,
under physiological conditions the picture is quite dif-
ferent. Tung used a titration method to study the con-
version of high-concentration ACP slurry to an apatite.
There was a typical conversion kinetics clearly indicating
two processes: the first process consumes acid, with the
conversion of ACP to an OCP-like intermediary and the
second process consumes base with the conversion of
the OCP-like intermediate to apatite or, possibly, direct
conversion of ACP to apatite. It was proposed that a
stoichiometric HAP could be formed when there is no
OCP-like intermediate phase, and a nonstoichiometric
apatite product could be formed when an OCP-like
intermediate phase is involved [28].
6. Biomedical and Dental Applications
ACP has been widely applied in biomedical field due to
its excellent bioactivity, high cell adhesion, adjustable
biodegradation rate and good osteoconduction [29-32].
As discussed above, the first quantitative studies on syn-
thetic ACP were done in the mid 1960s [1]. From then
on, more and more attention has been attracted in the
development and the application of ACP-containing pro-
ducts, especially in orthopedic and dental fields. It is also
used as filler in ionomer cements to fill carious lesions or
as a colloidal suspension in toothpastes, chewing gums or
mouthwashes to promote demineralization of carious
lesions and/or to prevent tooth demineralization.
6.1 CPP-ACP
Casein phosphopeptides (CPP) contain the cluster
sequence of -Ser (P)-Ser (P)-Ser (P)-Glu-Glu from
casein [33,34]. Through these multiple phosphoseryl
residues, CPP has a remarkable ability to stabilize clus-
ters of ACP into CPP-ACP complexes, preventing their
growth to the critical size required for nucleation, phase
transformation and precipitation. In the United States,
up to now, this product is primarily used for abrasive
prophylaxis pastes and secondarily used for the treat-
ment of tooth sensitivity especially after in-office bleach-
ing procedures, ultrasonic scaling, hand scaling or root
planing. However, its use for remineralizing dentin and
enamel and preventing dental caries is an off-label appli-
cation. Outside the United States, this product is mar-
keted as GC Tooth Mousse [35,36].
A clinical trial of a mouthwash containing CPP-ACP
showed that the contents of calcium and inorganic
phosphate in supragingival plaque increased after use of
the mouthwash for a three-day period [37]. Rose mea-
sured the affinity of Streptococcus mutans to CPP-ACP.
It was demonstrated that CPP-ACP bound with about
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ACP binds well to plaque, providing a large calcium
reservoir within plaque and slowing diffusion of free cal-
cium. Additional evidence reported also by Rose indi-
cates that CPP-ACP would compete with calcium for
plaque Ca binding sites. As a result, this will reduce the
amount of calcium bridging between the pellicle and
adhering bacterial cells and between bacterial cells
themselves [39]. This is likely to restrict mineral loss
during a cariogenic episode and provide a potential
source of calcium for the inhibition of demineralization
and assist in subsequent remineralization.
A human in situ caries model has been used by Rey-
nolds to study the ability of 1.0% CPP, 60-mM CaCl2
and 36-mM sodium phosphate, pH 7.0, solution to pre-
vent enamel demineralization [40]. Two exposures of
CPP-ACP solution per day to one side of the enamel
slabs produced 51 ± 19% reduction in enamel mineral
loss compared to the control side. Plaque exposed to
CPP-ACP had 2.5 times more Ca and phosphorus than
control plaque [36]. Reynolds also used an in vitro
model system to study the effects of CPP-ACP solutions
on remineralization of artificial lesions in human third
molars. After a ten-day remineralization period, all solu-
tions deposited mineral into the bodies of the lesions,
with 1.0% CPP-ACP (pH 7.0) solution replacing 63.9 ±
2 0 . 1 %o fm i n e r a ll o s ta ta na v e r a g e dr a t eo f3 . 9±0 . 8×
10
-8 mol hydroxyapatite/m
2/s. The remineralizing capa-
city was greater in the solutions with higher levels of
CPP-stabilized free calcium and phosphate ions [41].
CPP-ACP and fluoride were shown to have additive
effects in reducing caries experience [42]. Thus CPP-
ACFP would add into the current fluoride-containing
dentifrices as a toothpaste additive to improve the effi-
cacy. Recent studies indicate that CPP-ACP can be
incorporated into confectionery and drinks without
adverse organoleptic effects [43]. CPP-ACP is a natural
derivative of milk, therefore could have an important
role as a food additive for the prevention of dental caries
[44]. However, in 2008 Azarpazhooh systemically
reviewed 98 articles on the clinical efficacy of casein
derivatives and concluded that there was insufficient evi-
dence (in quantity, quality or both) in existing clinical
trials to make a recommendation regarding the long-
term effectiveness of casein derivatives, specifically CPP-
ACP, in preventing caries in vivo and treating dentin
hypersensitivity or dry mouth [34].
6.2 ACP-filled polymeric composites
ACP has been evaluated as a filler phase in bioactive
polymeric composites [45]. Skrtic has developed unique
biologically active restorative materials containing ACP
as filler encapsulated in a polymer binder, which may
stimulate the repair of tooth structure because of
releasing significant amounts of calcium and phosphate
ions in a sustained manner [46-49]. In addition to excel-
lent biocompatibility, the ACP-containing composites
release calcium and phosphate ions into saliva milieus,
especially in the oral environment caused by bacterial
plaque or acidic foods. Then these ions can be deposited
into tooth structures as apatitic mineral, which is similar
to the hydroxyapatite found naturally in teeth and bone
[50,51].
However, it was reported that the orthodontic ACP-
containing adhesive showed lower bond strength. Dunn
conducted an in vitro study to compare ACP-containing
vs. conventional resin-based orthodontic adhesives [52].
Foster also compared the shear bond strength of ortho-
dontic brackets using ACP-containing adhesive with a
conventional adhesive and a resin-modified glass iono-
mer. In both studies, ACP-containing adhesive was
demonstrated with lower, but clinically satisfactory bond
strength as an orthodontic adhesive [53]. When compar-
ing four new ACP-containing bonding systems, includ-
ing Aegis Ortho, with a conventional bracket bonding
system (Transbond XT), it was found that the tradi-
tional bonding systems achieved greater bond strengths
than the newer ACP-containing ones. According to the
study, however, Aegis Ortho had bond strengths suffi-
cient for orthodontic use at 24-hour post-cure time. But
the bracket might drift because of low viscosity of the
material during laboratory bonding. The authors also
found that Aegis Ortho had lower flexural strength,
which would explain for the material failure at the adhe-
sive-bracket interface rather than the enamel adhesive
interface [54].
Compared with more commonly used silanated glass
or ceramic filler, more hydrophilic and biodegradable
ACP-filled composites exhibited inferior mechanical
properties, durability and water sorption characteristics
[55]. The uncontrolled aggregation of ACP particulates
along with poor interfacial interaction plays a key role
in adversely affecting their mechanical properties [56].
Their clinical applicability may be compromised by rela-
tively poor filler/matrix interfacial adhesion and also by
excessive water sorption that occurs in both resin and
filler phases of these composites [42,46].
H o w e v e r ,i th a sb e e nd e m o n s t r a t e dt h a ti ti sp o s s i b l e
to improve the remineralizing potential of ACP compo-
sites by introducing Si or Zr elements during low-tem-
perature synthesis of the filler. Si- and Zr- ACPs
enhanced the duration of mineral ion release through
their ability to slow down the intra-composite ACP to
HAP conversion [57]. It was also possible that non-ionic
and anionic surfactants and poly (ethylene oxide) (PEO)
introduced during the preparation of ACP play a role
on the particle size distribution and compositional prop-
erties of ACP fillers [58]. The hydrophilic PEO is widely
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proven ability to undergo multiple hydrogen bonding
interactions and stabilize cations by multiple chelation.
The incorporated PEO in ACP fillers would also be
expected to affect ACP’s tendency to form aggregates
and the water content of the ACP-containing composites.
These properties would eventually affect both ion release
kinetics and mechanical stability of composites [59]. It
was found that surfactants introduced during the precipi-
tation of ACP stabilized the amorphous solid phase
against the conversion to apatite. The particle size of
ACP was moderately reduced because of the introduction
of anionic surfactant. Addition of PEO resulted in more
pronounced ACP agglomeration but no changes of
ACP’s water content. Both surfactants and PEO lead to
no changes in dry biaxial flexure strength of composites
compared to the control Zr-ACP composites. However,
their strength was drastically reduced in contrast to the
control after prolonged exposure to aqueous milieu.
6.3 ACP in bone repair materials
Various compounds from calcium phosphate family
have been extensively investigated as hard tissue repair
materials due to their excellent biocompatibility [60]. It
has been shown that the rate of new bone formation
coincides more closely with the resorption rate of poorly
crystalline apatites and A C P[ 6 1 ] .A d d i t i o n a l l y ,A C P
showed better osteoconductivity in vivo than apatite and
its biodegradability was higher than that of tricalcium
phosphate [25].
Clinically, it is widely accepted to use autograft and
allograft materials to repair bone defects [29]. Recently,
materials with ACP, hydroxyapatite and other calcium
phosphate family members have been extensively inves-
tigated for alternative bone repair due to the limitations
of traditional materials such as potential immunogeni-
city, insufficient supply and so on [62,63]. ACP and
ACP/biopolymer composites have emerged as a new
class of bone tissue engineering scaffold materials. Their
excellent biocompatibility and osteoconductibility make
them great materials for bone substitution and repair.
It has been shown that bone-like apatite materials
have optimal surface characteristics for osteoblast cells
to adhere, proliferate and differentiate, as a result, to
favor bone formation and regeneration. An amorphous
carbonated calcium phosphate ceramic was encapsulated
within bioresorbable PLAGA microspheres and sintered
to form a bioresorbable, highly porous, 3-dimensional
scaffold. These noncrystalline and carbonated materials
may be ideal for tissue ingrowth and potentially suitable
for bone repair applications [64].
ACP was also incorporated into porous poly (L-lactic
acid) (PLLA) to create a desired pore wall surface within
bone tissue engineering scaffolds [65]. After being soaked
in PBS, ACP aggregates in the composite experienced a
fast and in situ transformation into bone-like apatite. The
cell culture results also demonstrated that ACP/PLLA
composite had an enhancement in cytocompatibility [65].
It has been demonstrated that ACP/PLLA material,
which can experience morphological variations in the
microstructure is also supposed to be a suitable candidate
as scaffold for cartilage tissue engineering [63,65].
7. Conclusions
ACP is usually formed as a metastable phase when cal-
cium and phosphate ions in aqueous solution react to
precipitate. The x-ray diffraction pattern, structure, mor-
phology and infrared analysis results of ACP solids show
typical noncrystalline characters within short-range
order, instead of long-range periodic regularity. ACP act
as an important intermediate product for in vitro and in
vivo apatite formation. A variety of proteins and ions can
increase the stability of ACP. ACP becomes increasingly
significant in orthopedics and dentistry because of their
excellent biocompatibility and mechanical properties. It
is believed that ACP will be used even more extensively
in the future due to due to the fast development of tissue
engineering techniques and applied material science.
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